Tango Therapeutics (TNGX) Non-Current Deffered Revenue (2020 - 2025)

Tango Therapeutics' Non-Current Deffered Revenue history runs 6 years deep, the most recent figure standing at $30.4 million for Q2 2025.

• On a quarterly basis, Non-Current Deffered Revenue fell 44.09% year-over-year to $30.4 million in Q2 2025; TTM through Jun 2025 was $30.4 million, a 44.09% decrease from a year earlier, with the FY2024 full-year figure at $44.8 million, down 32.87% from the prior year.
• Non-Current Deffered Revenue retreated to $30.4 million in Q2 2025 per TNGX's latest filing, from $37.5 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $116.6 million in Q3 2021 and bottomed at $5.8 million in Q1 2021.
• The 5-year median for Non-Current Deffered Revenue is $68.7 million (2023), against an average of $68.3 million.
• Across the five-year window, Non-Current Deffered Revenue surged 1898.7% in 2021 and tumbled 44.09% in 2025, its largest moves.
• Year by year, Non-Current Deffered Revenue stood at $114.7 million in 2021, then fell by 19.73% to $92.1 million in 2022, then declined by 27.59% to $66.7 million in 2023, then tumbled by 32.87% to $44.8 million in 2024, then slumped by 32.01% to $30.4 million in 2025.
• Per Business Quant, the three latest TNGX Non-Current Deffered Revenue figures stand at $30.4 million (Q2 2025), $37.5 million (Q1 2025), and $44.8 million (Q4 2024).